Enorama Pharma (ERMA) Q2 2024 earnings summary

Executive summary

• Net sales for H1 2024 increased to 5,646 KSEK from 1,135 KSEK year-over-year, driven by US pouch sales.

• Operating loss narrowed to -16,366 KSEK from -18,449 KSEK for H1 2024.

• Strategic focus on US market expansion, new production agreement, and transition to commercial phase.

• CEO transition and strengthened commercial strategy for US growth.

Financial highlights

• Q2 2024 net sales reached 5,656 KSEK, up from 457 KSEK in Q2 2023.

• Q2 operating loss improved to -6,340 KSEK from -8,695 KSEK year-over-year.

• H1 2024 pre-tax loss was -14,673 KSEK, compared to -17,878 KSEK in H1 2023.

• Cash and cash equivalents at June 30, 2024 were 17,376 KSEK, up from 247 KSEK a year earlier.

• Equity increased to 38,754 KSEK from 12,726 KSEK year-over-year.

Outlook and guidance

• Focus remains on US market expansion, especially for white snus products.

• Ongoing evaluation of financing options to support PMTA process and US go-to-market activities.

• Increased production capacity expected to support future sales growth.